France Generics and Biosimilars
France Generics and Biosimilars
$2,995.00
Traditionally considered an immature generics market, France has seen the introduction of measures aimed at increasing generics use in order to cut healthcare costs.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
Traditionally considered an immature generics market, France has seen the introduction of measures aimed at increasing generics use in order to cut healthcare costs.
However, while generics uptake has increased as a result of pro-generics measures introduced over the past few years, physician reluctance remains the key obstacle to increased generics dispensing, with new measures aimed at pharmacists designed to increase substitution levels.
In addition, continued price cuts threaten generics profitability, with weak attempts to change physician prescribing practices indicating generics uptake will continue to rise slowly.
Table of Contents
4 EXECUTIVE SUMMARY
4 Generics market
4 Biosimilars market
5 GENERICS MARKET DYNAMICS
6 France generics volume uptake
7 France generics value uptake
8 France generics market size
9 Drivers and resistors to generics uptake in France
15 BIOSIMILARS MARKET DYNAMICS
15 Drivers of and resistors to biosimilar uptake in France
17 Approved biosimilars
19 Branded monoclonal antibody therapies facing biosimilar incursion
23 BIBLIOGRAPHY
List of Figures
7 Figure 1: Comparison of generic volume uptake versus other major pharmaceutical markets (%), 2009–11
7 Figure 2: Comparison of generic value uptake versus other major pharmaceutical markets (%), 2009–11
8 Figure 3: Comparison of generics market size in France versus other pharmaceutical markets, 2009–11
10 Figure 4: France – key factors influencing the generics industry, 2013
15 Figure 5: France – key factors influencing the biosimilar industry, 2013
21 Figure 6: France – drivers of and resistors to biosimilar MAb entry, 2013
List of Tables
5 Table 1: Generics uptake and market size in France in relation to other major pharmaceutical markets, 2009–11
16 Table 2: France – biologic and biosimilar prices listed in the French National Drug Formulary, 2008–10
17 Table 3: Biosimilars approved and rejected in the five major EU markets, 2012
Figure 1: Comparison of generic volume uptake versus other major pharmaceutical markets (%), 2009–11
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Russia Generics and Biosimilars 
Sign up to the